This invention disclosed medical catheters with surface hydrophilic coatings. Said catheters were grafted with a thin layer of zwitterions, which forms lubricious water layer when contacted with human body liquids or other water solutions, to lower the surface friction and mechanical damage to human body. One benefit of the present invention is due to the excellent biocompatibility and tight bonding between modification material and catheter substrate, the modification will stably stay on the substrate during usage, to avoid the potential side effects caused by lubricants. This modification can be applied to multiple material surfaces, including but not limited to silicone rubber, polyurethane, rubber, polyetheretherketone, polyethylene, polypropylene, polyvinyl chloride, nylon, ABS (Acylonitrile Butadiene Styrene), and polycarbonate.

The present invention relates to a porous biocompatible implant and a method for manufacturing the same, and more specifically to a porous biocompatible implant in which osseointegration is excellent, no dissociation from the implant occurs, the inflammatory response caused by metals or bacteria can be minimized, and it is possible to accelerate bone formation, while having excellent mineralized bone formation performance, and a method for manufacturing the same. In addition, the porous biocompatible implant of the present invention can be widely used in clinical practices such as dentistry and orthopedic surgery.

A tacrolimus drug-eluting stent manufacturing method according to the present invention enables a tacrolimus drug to be strongly and stably bound onto a stent, while also not necessarily involving a separate step of introducing a surface-binding functional group for the binding of a drug onto a stent and a step of introducing, into the drug, a functional group capable of binding to the surface-binding functional group, and a tacrolimus drug-eluting stent manufactured by the manufacturing method has a greater total drug elution amount and has a more excellent delayed drug-elution property.

Embodiments of the invention include apparatus and methods for coating drug coated medical devices. In an embodiment, the invention includes a coating apparatus including a coating application unit. The coating application unit can include a fluid applicator having a lengthwise axis and a width. The fluid applicator can include a tip comprising a first face across the width of the fluid applicator. The first face of the fluid applicator can be oriented at an angle of from about 15 to about 75 degrees with respect to the lengthwise axis of the fluid applicator. The fluid applicator can define a second face intersecting the first face. The coating apparatus can further include a rotation mechanism and an axial motion mechanism. Other embodiments are also included herein.

A medical stent may include a tubular support structure including a plurality of struts defining a plurality of cells disposed between the plurality of struts. A polymeric coating may be disposed over the tubular support structure such that a first portion of the plurality of cells are closed by the polymeric coating in a first region of the tubular support structure and a second portion of the plurality of cells in a second region of the tubular support structure remain open to fluid flow and/or tissue ingrowth therethrough. The struts in the first region of the tubular support structure and the struts in the second region of the tubular support structure may be at least partially covered by the polymeric coating.

An implantable medical device includes a polymer substrate and at least one nanofiber. The polymer substrate includes a surface portion extending into the polymer substrate from a surface of the substrate. The at least one nanofiber includes a first portion and a second portion. The first portion is interpenetrated with the surface portion of the substrate, and mechanically fixed to the substrate. The second portion projects from the surface of the substrate.

The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

An anti-fouling implantable material and a method of making the anti-fouling implantable material are disclosed. The anti-fouling implantable material includes a polymeric reinforcement layer, an intermediate layer comprising a protective polymer membrane, and an outer layer comprising an ionic polymer. The anti-fouling implantable material may have chemical and/or physical properties compatible with body tissue properties. The anti-fouling implantable material may be used for implantable medical devices, such as prosthetic heart valves and vascular grafts, among others.

Embodiments include formulations and methods for topical administration of sugar alcohol to treat a skin condition such as acne. A formulation can include a moisturizer, an emollient, a sugar alcohol and zinc. The sugar alcohol can be erythritol. The erythritol can be administered with zinc chloride. The erythritol and zinc chloride can be formulated at a molar ratio of about 3:1. The methods can also include administration of a therapeutic amount of a second agent such as benzoyl peroxide or a retinoid. Embodiments also include antimicrobial coatings that contain erythritol and zinc to reduce, negate, and prevent the proliferation and propagation of accumulating biofilm. The formulation can be used to clean and/or provide an antimicrobial coating on a medical device such as a catheter.

A medical device includes a substrate structure with a surface. The surface is laser treated to define at least one protrusion and/or at least one void extending relative to the surface. A coating having antibacterial, antimicrobial and/or drug eluding properties is applied to the substrate structure such that the coating engages within or along a surface portion of one or more of the protrusions and/or voids.